期刊
JOURNAL OF MEDICAL VIROLOGY
卷 93, 期 1, 页码 546-549出版社
WILEY
DOI: 10.1002/jmv.26279
关键词
coronavirus; COVID-19; exacerbation; fingolimod; multiple sclerosis; SARS-CoV-2
类别
Discontinuation of fingolimod during COVID-19 may worsen SARS-CoV2 infection, leading to hyperinflammation syndrome.
The role of disease-modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease-2019 (COVID-19) due to the absence of an adequate immune response against the SARS-CoV-2. However, therapies that act on immune response could play a protective role by dampening the cytokine-release syndrome. Fingolimod is a drug used for immune therapy in patients with multiple sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57-year-old man with relapsing-remitting MS treated with fingolimod that showed a reactivation of COVID-19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID-19 could imply a worsening of SARS-CoV2 infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据